NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Incorporated (OTCBB: ADXS), has updated survival data for its Phase I trial of its live Listeria vaccine ADXS11-001(formerly named Lovaxin-C) in patients with recurrent, metastatic, carcinoma of the cervix. While the Phase I safety trial was not designed to evaluate efficacy or survival as its primary endpoints, Advaxis has continued to follow the survival of the study participants.
